976-71-6
基本信息
刊利酮
卡利酮
烯睾丙内酯
坎利酮-D4
螺内酯相关物质A
安体舒通EP杂质F
依普利酮CANRENONE杂质
6-去氢睾(甾)酮-17α-丙酸-γ-内酯
雄甾-4,6-二烯-17β-醇-3-酮-17α-丙酸内酯
11614r.p
phanurane
CANRENONE
ALDADIENE
NSC 261713
CANRENONE-D4
Canrenone, >=97%
Canrenone98.5%Min
spirolactonesc14266
物理化学性质
| 外观性状 | 微黄色或乳白色结晶性粉末(乙酸乙酯)。熔点149-151℃,165℃固化并重熔。 |
| 熔点 | 158-1600C |
| 比旋光度 | D +24.5° (chloroform) |
| 沸点 | 416.25°C (rough estimate) |
| 密度 | 1.1236 (rough estimate) |
| 折射率 | 1.5000 (estimate) |
| 储存条件 | Store at RT |
| 溶解度 | 在DMSO中的溶解度为20mg/mL,澄清 |
| 形态 | 粉末 |
| 颜色 | 白色至米色 |
| 旋光度 (Optical Rotation) | [α]/D +17 to +24°, c = 1 in chloroform-d |
| 水溶解性 | 272.4ug/L(25 ºC) |
| 主要应用 | pharmaceutical (small molecule) |
| InChI | InChI=1/C22H28O3/c1-20-9-5-15(23)13-14(20)3-4-16-17(20)6-10-21(2)18(16)7-11-22(21)12-8-19(24)25-22/h3-4,13,16-18H,5-12H2,1-2H3/t16-,17+,18+,20+,21+,22-/s3 |
| InChIKey | UJVLDDZCTMKXJK-MUWITHSMNA-N |
| SMILES | [C@@]12(CCC(=O)O1)CC[C@@]1([H])[C@]3([H])C=CC4=CC(=O)CC[C@]4(C)[C@@]3([H])CC[C@]21C |&1:0,8,10,20,22,26,r| |
| LogP | 2.54 at 25℃ |
| CAS 数据库 | 976-71-6 |
| NIST化学物质信息 | Canrenone(976-71-6) |
安全数据
| 危险性符号(GHS) | ![]() ![]() GHS08,GHS09 |
| 警示词 | 警告 |
| 危险性描述 | H351-H411 |
| 防范说明 | P280 |
| 危险品标志 | Xn,N |
| 危险类别码 | 40-51/53 |
| 安全说明 | 36/37-61 |
| 危险品运输编号 | UN 3077 9 / PGIII |
| WGK Germany | 3 |
| REACH 注册登记 | Active |
| 危险等级 | 9 |
| 海关编码 | 29329990 |
| 存储类别 | 11 - Combustible Solids |
| 危险性类别 | Aquatic Chronic 2 Carc. 2 Oral |
制备方法
坎利酮价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2026/09/15 | HY-B1438R | 坎利酮 Canrenone (Standard) | 976-71-6 | 10 mg | 250元 |
| 2026/09/15 | HY-B1438R | 坎利酮 Canrenone (Standard) | 976-71-6 | 25 mg | 450元 |
| 2026/09/15 | HY-B1438R | 坎利酮 Canrenone (Standard) | 976-71-6 | 50 mg | 750元 |
常见问题列表
|
Human Endogenous Metabolite
|
Canrenone inhibits the production of eortieosterone, 18-hydroxydesoxyeortieosterone, 18-hydroxycorticosterone and aldosterone in a dose-dependent manner. Canrenone dose-dependently reduces platelet-derived growth factor–induced cell proliferation and motility. Canrenone inhibits the activity of the Na + /H + exchanger 1 induced by platelet-derived growth factor.
Canrenone is the principal active metabolite of Spironolactone in the rat only for a limited period. During chronic treatment a difference developed between the effect of Spironolactone and Canrenone on the RAAS indicating a decrease in the anti-mineralocorticoid activity of Canrenone and an increase in the efficacy of Spironolactone.

